Across TCGA pan-cancer cohorts, TAF13 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TAF13 data layer compared with 24 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TAF13 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated TAF13 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

CCRCC, HNSC, and UCEC are the cancer types where TAF13 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Quartile	II,III,IV	0.669	1.000	.010	10	view →
HNSC	DFS	Tertile	III,IV	0.740	0.928	.016	6	view →
UCEC	OS	Median	All	1.000	0.842	.033	6	view →
PDAC	DFS	Median	All	0.445	0.865	.038	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: TAF13 tumor-vs-normal RNA expression · all TAF13 data types